^
Association details:
| Biomarker: | FGFR2 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug Class: | FGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Published date:
11/10/2022
Excerpt:
FGFR inhibitors are recommended for the treatment of patients with FGFR2 fusions whose disease has progressed after ≥1 prior line of systemic therapy.
Source:
Title:
ctDNA-based genomic landscape analysis to evaluate molecular brake and gatekeeper mutations in FGFR2 alterations.
Published date:
05/25/2023
Excerpt:
We also identified CCA patients with FGFR2 fusions and one or more concurrent FGFR2 SNVs; primarily those in the kinase domain and associated with FGFRi resistance.
DOI:
10.1200/JCO.2023.41.16_suppl.3049
Source:
Title:
FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience
Excerpt:
Our group identified 61 patients with advanced or metastatic CCA, 19 males (31%) and 42 females (69%), harboring FGFR alterations who received FGFRi….Median progression-free survival on FGFRi was 5.8 months for all patients (95% CI, 4.9 to 9.0). Median OS from time of FGFRi initiation for patients with FGFR2 fusion or rearrangement was 20.2 months (95% CI, 11.8 to 38.3) compared to patients with other FGFR alterations at 13.0 months....FGFRi are well tolerated with clinical efficacy.
DOI:
10.1200/PO.21.00064
